Human neural organoid modeling of alzheimer's disease neuroinflammation for drug discovery
Ended Project Grant Awarded Last action
- Award ID
- R43AG082625
- Recipient
-
Stem Pharm, Incorporated UEI YTLQLAJ53CB7
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,054,806
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date
- Originally
- Place of performance
- Wisconsin, USA
Award details come from USAspending.gov.
Description
- Abstract
- Alzheimer's disease (ad) is the most prevalent neurodegenerative disease with more than 6.5 million americans currently living with ad dementia. Ad is defined by its neuropathological hallmarks which include ASS peptide plaque deposits, intraneuronal TAU tangles and neuronal loss. A major component of the ad process is neuroinflammation. Genome-wide association studies (GWAS) have revealed several immune genes which are risk factors for developing late-onset ad. Several of these ad risk genes such as SPI1 and TREM2 are highly expressed in microglia, the brain's resident macrophage-like population. Microglia phagocytose ASS and play a central role in the brain's response to amyloid plaques and the neurodegenerative process. While pluripotent stem cell-derived neural organoids do not typically contain immune cell populations, stem pharm's hydrogel-enabled neural organoids allow for incorporation of microglia in a reproducible, 96-well plate format amenable to screening applications. Using this technology, our preliminary data demonstrate microglia incorporate into the neural organoids and respond appropriately to inflammatory stimuli including ASS oligomers and apoptotic neurons. Work in this proposal will lead to the generation of a human ad-neuroinflammation organoid model by exposing cultures with oligomeric ASS and apoptotic neuronal cells to induce ad-like neuroinflammatory responses, ultimately enabling a more biologically relevant human ad model for drug discovery applications focused on immune modulation. Specific aims will 1) optimize the model and establish the gene expression signature of the microglia; 2) and incorporate microglia engineered with mutations in the ad associated gene TREM2. Completion of these specific aims will establish a flexible neuroinflammation model system capable of screening the effects of compounds or incorporating microglia harboring mutant ad-associated genes. Phase II studies will seek to expand the capabilities of the model by establishing and optimizing readouts to measure the effect of inflammation on the neuronal cell populations and establish organoids from additional donors. Ultimately, this work will develop commercially available, novel models of the ad inflammation process which can serve to supplement the many rodent model systems currently available.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $55,000 | |
| Amendment | $499,903 | |
| Original award | $499,903 |
Quick answers
Who received award R43AG082625?
R43AG082625 was awarded to Stem Pharm, Incorporated by National Institute on Aging (National Institutes of Health) on September 1, 2023.
How much is award R43AG082625 worth?
$1,054,806 has been obligated on R43AG082625.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award